Influence of osteoclasts and osteoprotegerin on the mode of calcific degeneration of aortic valves.

INTRODUCTION Calcific aortic valve disease is associated with inflammation and calcification, thus the osteoprotegerin (OPG), receptor activator of nuclear factor κB (RANK) and its ligand (RANKL) system involved in osteoclastogenesis and inflammation may play a significant role in valve degeneration. OBJECTIVES The aim of this study was to assess whether circulating OPG, sRANKL, and other bone metabolism markers can predict the presence of osteoclasts in stenotic valves and to evaluate their impact on the mode of degeneration. PATIENTS AND METHODS The study involved 60 patients with aortic stenosis who underwent valve replacement surgery and subsequently were divided into 2 groups: osteoclastic (n = 12) and nonosteoclastic (n = 48), according to the presence or absence of intravalvular osteoclasts. Before the surgery, we measured serum levels of OPG, sRANKL, osteocalcin, osteopontin, tumor necrosis factor α (TNF-α), interleukin (IL) 1β, and IL-6. Immunohistochemistry and morphometry were used to determine the extent of valve calcification, lipid accumulation, neovascularization, and the number and phenotype of macrophages. RESULTS Compared with the nonosteoclastic group, patients with intravalvular osteoclasts had lower levels of OPG (P = 0.0006) and TNF-α (P = 0.02) and less frequently had diabetes (P = 0.04). Their valves showed higher incidence of ossification (P = 0.002), higher total (P = 0.008) and M2 macrophage counts (P = 0.0002), increased neovascularization (P = 0.003), and lower accumulation of lipids (P = 0.04). They also showed a negative correlation between valve calcification and age (r = -0.79, P = 0.002), which was not observed in patients without osteoclasts. In a multivariate analysis, low circulating OPG levels and the absence of diabetes were predictors of intravalvular osteoclastic differentiation. CONCLUSIONS The presence of osteoclasts in stenotic valves associated with low circulating OPG levels and an enhanced proportion of M2 macrophages can represent a variant of calcific aortic valve disease with a specifically regulated calcification process.

[1]  M. Lindsey,et al.  Deriving a cardiac ageing signature to reveal MMP-9-dependent inflammatory signalling in senescence. , 2015, Cardiovascular research.

[2]  W. Kwiatek,et al.  Distribution of selected elements in calcific human aortic valves studied by microscopy combined with SR-μXRF: influence of lipids on progression of calcification. , 2014, Micron.

[3]  Klaus Ley,et al.  M1 and M2 Macrophages: The Chicken and the Egg of Immunity , 2014, Journal of Innate Immunity.

[4]  J. Nessler,et al.  Elevated serum osteoprotegerin is associated with decreased osteoclastic differentiation in stenotic aortic valves. , 2014, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[5]  R. Morishita,et al.  OPG/RANKL/RANK axis is a critical inflammatory signaling system in ischemic brain in mice , 2014, Proceedings of the National Academy of Sciences.

[6]  K. Fujiu,et al.  Cardioprotective function of cardiac macrophages. , 2014, Cardiovascular research.

[7]  P. Dimitrow Aortic stenosis: new pathophysiological mechanisms and their therapeutic implications. , 2014, Polskie Archiwum Medycyny Wewnetrznej.

[8]  P. Pellikka,et al.  Relation of osteoprotegerin in severe aortic valve stenosis to postoperative outcome and left ventricular function. , 2013, The American journal of cardiology.

[9]  E. Ingelsson,et al.  Valvular osteoclasts in calcification and aortic valve stenosis severity. , 2013, International journal of cardiology.

[10]  A. Kraśniak,et al.  Osteoprotegerin as a marker of cardiovascular risk in patients on peritoneal dialysis. , 2013, Polskie Archiwum Medycyny Wewnetrznej.

[11]  Yoshiya Tanaka,et al.  Interleukin-1β induces differentiation of human mesenchymal stem cells into osteoblasts via the Wnt-5a/receptor tyrosine kinase-like orphan receptor 2 pathway. , 2012, Arthritis and rheumatism.

[12]  T. Rachner,et al.  Skeletal and extraskeletal actions of denosumab , 2012, Endocrine.

[13]  J. Schrooten,et al.  Mechanisms of ectopic bone formation by human osteoprogenitor cells on CaP biomaterial carriers. , 2012, Biomaterials.

[14]  O. Alfieri,et al.  Type 2 diabetes mellitus is associated with faster degeneration of bioprosthetic valve: results from a propensity score-matched Italian multicenter study. , 2012, Circulation.

[15]  R. Virmani,et al.  Hemoglobin directs macrophage differentiation and prevents foam cell formation in human atherosclerotic plaques. , 2012, Journal of the American College of Cardiology.

[16]  Yong Sun,et al.  Runx2-Upregulated Receptor Activator of Nuclear Factor &kgr;B Ligand in Calcifying Smooth Muscle Cells Promotes Migration and Osteoclastic Differentiation of Macrophages , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[17]  R. Weiss,et al.  Calcific Aortic Valve Stenosis: Methods, Models, and Mechanisms , 2011, Circulation research.

[18]  A. Gackowski,et al.  The influence of statins on levels of calcification biomarkers in patients with aortic sclerosis or mild aortic stenosis. , 2011, The Journal of heart valve disease.

[19]  J. Igland,et al.  Serum osteoprotegerin levels and long-term prognosis in patients with stable angina pectoris. , 2010, Atherosclerosis.

[20]  D. O'Gorman,et al.  Osteoprotegerin and biomarkers of vascular inflammation in type 2 diabetes , 2010, Diabetes/metabolism research and reviews.

[21]  R. Weissleder,et al.  Arterial and aortic valve calcification inversely correlates with osteoporotic bone remodelling: a role for inflammation , 2010, European heart journal.

[22]  Avijit Lahiri,et al.  Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. , 2010, Journal of the American College of Cardiology.

[23]  G. Nickenig,et al.  Differential profile of the OPG/RANKL/RANK-system in degenerative aortic native and bioprosthetic valves. , 2008, The Journal of heart valve disease.

[24]  A. Hayman Tartrate-resistant acid phosphatase (TRAP) and the osteoclast/immune cell dichotomy , 2008, Autoimmunity.

[25]  T. Sculco,et al.  Expression profiling reveals alternative macrophage activation and impaired osteogenesis in periprosthetic osteolysis , 2008, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[26]  P. Kovanen,et al.  Increased circulating concentrations and augmented myocardial extraction of osteoprotegerin in heart failure due to left ventricular pressure overload , 2007, European journal of heart failure.

[27]  R. Kronmal,et al.  Features of the Metabolic Syndrome and Diabetes Mellitus as Predictors of Aortic Valve Calcification in the Multi-Ethnic Study of Atherosclerosis , 2006, Circulation.

[28]  A. Zannettino,et al.  Osteoprotegerin (OPG) is localized to the Weibel‐Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor , 2005, Journal of cellular physiology.

[29]  K. Nitta,et al.  Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[30]  R. Detrano,et al.  Calcification in atherosclerosis: Bone biology and chronic inflammation at the arterial crossroads , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[31]  P. Pietschmann,et al.  Serum levels of osteoprotegerin increase with age in a healthy adult population. , 2003, Bone.

[32]  A. Tajik,et al.  Human Aortic Valve Calcification Is Associated With an Osteoblast Phenotype , 2003, Circulation.

[33]  Emile R. Mohler,et al.  Bone Formation and Inflammation in Cardiac Valves , 2001, Circulation.

[34]  F. Parhami,et al.  Tumor Necrosis Factor-&agr; Promotes In Vitro Calcification of Vascular Cells via the cAMP Pathway , 2000, Circulation.

[35]  D. Lacey,et al.  Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. , 1999, Bone.